ExactMeds by RxGenomix
Pharmacogenomics (PGx) medication-management program combining genetic testing with pharmacist counseling.
Website: https://exactmeds.com/
Cover Block
Publicly reported
| Field | Value |
|---|---|
| Name | ExactMeds by RxGenomix [ExactMeds by RxGenomix, retrieved 2024] |
| Tagline | Pharmacogenomics (PGx) medication-management program combining genetic testing with pharmacist counseling [RxGenomix, May 2024] |
| Headquarters | Franklin, TN [LinkedIn, retrieved 2024] |
| Founded | 2013 [LinkedIn, retrieved 2024] |
| Business Model | B2B2C |
| Industry | Healthtech |
| Technology | Biotech / Life Sciences |
| Geography | North America |
| Founding Team | Brad Tice, Victor Penev [RxGenomix, December 2022] [Md. Mahmudul Hasan - Oklahoma State University |
| Funding Label | Unfunded |
Links
Publicly reported
- Website: https://exactmeds.com/
- LinkedIn: https://www.linkedin.com/company/rxgenomix
- Product page: https://exactmeds.com/products/
- Get Started: https://exactmeds.com/product/exactmeds/
- ExactMeds App: https://rxgenomix.com/exactmeds-app/
Summary and Signal
PUBLIC ExactMeds, operated by RxGenomix, is a pharmacogenomics medication-management program that combines at-home genetic testing with pharmacist counseling, and it merits attention because it is trying to package a clinically complex service into a benefit and telehealth workflow that employers, pharmacists, and individual patients can actually buy today [RxGenomix, May 2024] [RxGenomix] [RxGenomix, December 2022]. The company was founded in 2013 and is based in Franklin, Tennessee, with public materials framing the mission around reducing trial-and-error prescribing by matching medication choices to a patient’s genetic profile [LinkedIn, retrieved 2024] [ExactMeds by RxGenomix, retrieved 2024].
The product stack is straightforward on paper: a home cheek-swab collection flow, testing through accredited clinical laboratories, a medication report, and a pharmacist-created action plan, with the company arguing that the differentiator is not the lab result alone but an ongoing pharmacist relationship and coordination with the patient’s clinicians [RxGenomix, May 2024] [RxGenomix] [RxGenomix, December 2022]. That positioning gives the company a clearer commercial wedge than many direct PGx offerings, particularly because RxGenomix also says it supports pharmacist education, implementation, and reimbursement workflows, which could matter if channel adoption comes through pharmacy partners rather than direct consumer acquisition [RxGenomix, December 2022].
On team quality, the public record is anchored by founder and CEO Brad Tice, a pharmacist who previously served as president of the American Pharmacists Association for 2019 to 2020, a credential that lends category credibility even if the broader executive bench is only lightly documented in public sources [RxGenomix, December 2022] [California Pharmacists Association, retrieved 2026] [Lead411, retrieved 2026]. A second name, Victor Penev, appears in association with ExactMeds in a LinkedIn reference, but the role and depth of involvement are not well established from the available evidence [LinkedIn, retrieved 2026].
The financing picture is thin. No confirmed venture rounds, named investors, or accelerator affiliations surfaced in the cited materials, so the company should be treated as unfunded on the public record, while the operating model appears B2B2C with routes into employers, benefit providers, pharmacists, healthcare providers, and direct-pay individuals [RxGenomix, December 2022] [The Covington Reporter, June 2024]. Pricing also appears segmented by channel, with company materials listing an employer-sponsored program at $299 for qualifying members and third-party coverage describing a $499 consumer-facing offer, which suggests packaging flexibility but also leaves open questions on reimbursement, conversion, and gross margin by cohort [RxGenomix, December 2022] [The Covington Reporter, June 2024].
Over the next 12 to 18 months, the main watchpoints are less about product concept and more about proof: independently verifiable customer deployments, evidence that the pharmacist-led model converts into recurring employer or channel revenue, and clearer public validation beyond company-authored case studies, including one 2022 insurer-related case study that does not name the insurance partner [ExactMeds by RxGenomix, retrieved 2024] [RxGenomix, December 2022]. The bet is understandable, but at this stage the public evidence base still rests heavily on company materials rather than third-party reporting or disclosed operating metrics.
No independent source found -- This section relies primarily on company websites and one third-party review, with no confirmed funding disclosures or independently verified traction metrics.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Business Model | B2B2C |
| Industry / Vertical | Healthtech |
| Technology Type | Biotech / Life Sciences |
| Geography | North America |
| Founding Team | Solo Founder |
| Funding | Unfunded |
Company Overview
PUBLIC
ExactMeds sits in a narrower lane than many consumer genomics offerings. The company presents the program as a pharmacogenomics medication-management service operated by RxGenomix, with the core promise that genetic testing is paired with pharmacist interpretation rather than delivered as a standalone lab result [ExactMeds by RxGenomix, retrieved 2024] [RxGenomix, May 2024]. Public company materials place the business in Franklin, Tennessee, and date RxGenomix to 2013, with Brad Tice identified as founder and chief executive [LinkedIn, retrieved 2024] [RxGenomix, December 2022].
The public record is thin on formal corporate milestones, but the chronology that can be supported is reasonably clear. RxGenomix's December 2022 materials describe ExactMeds as a program sold across several channels, including individuals, healthcare providers, pharmacists, employers, and benefit providers, while also emphasizing pharmacist training, implementation support, and reimbursement guidance as part of the operating model [RxGenomix, December 2022]. By May 2024, the company's patient-facing materials described an at-home sample collection workflow, external accredited laboratory testing, and pharmacist review of results, which suggests the service had matured into a defined care pathway rather than a simple testing offer [RxGenomix, May 2024]. Separate product pages retrieved in 2024 also frame ExactMeds as both an individualized benefit and an employer-oriented program, including a 2022 case study tied to an unnamed large insurance partner [ExactMeds by RxGenomix, retrieved 2024].
The legal entity name is not independently established in the available public sources beyond the brand relationship between ExactMeds and RxGenomix. No confirmed funding rounds, accelerator participation, or state filing details were surfaced in the materials provided, so the company overview rests largely on first-party disclosures and LinkedIn profile data [LinkedIn, retrieved 2024] [RxGenomix, December 2022].
No independent source found -- This section relies primarily on company website materials, with limited corroboration from LinkedIn.
The Product and the Stack
MIXED Product configuration and delivery
ExactMeds is presented as a pharmacogenomics medication-management service rather than a standalone testing product. Public company materials describe a workflow that starts with an at-home cheek-swab collection kit, moves through laboratory PGx testing performed by accredited clinical testing laboratories, and ends with a medication report plus a pharmacist-created action plan [RxGenomix, May 2024]. RxGenomix also says it is a PGx services company, not a laboratory itself, which matters because the technical claim here rests more on orchestration, interpretation, and care delivery than on ownership of the testing infrastructure [RxGenomix, May 2024].
The patient-facing experience appears to be built around pharmacist interpretation as the core layer of the product. RxGenomix says results are reviewed with a certified pharmacist who can explain findings, review current medications, and help coordinate recommendations with clinicians, while the ExactMeds app is described as a secure interface connecting users with a Personal Pharmacist and producing a personalized Medication Action Plan [RxGenomix]. An independent local review from June 2024 similarly described ExactMeds as an online medication and telehealth service using genetic testing to personalize medication recommendations, which partially corroborates the company's positioning even if the underlying clinical and commercial claims remain mostly company-sourced [The Covington Reporter, June 2024].
MIXED Commercial packaging and technical differentiation
The clearest public differentiation claim is not a proprietary assay or model layer, but the pairing of PGx results with ongoing pharmacist support. RxGenomix markets ExactMeds to individuals, healthcare providers, pharmacists, employers, and benefit providers, and says it provides pharmacist education, implementation support, and reimbursement guidance so consultations can become an additional reimbursed service inside pharmacy practice [RxGenomix, December 2022]. That suggests the technology is being packaged as both a consumer-facing care experience and a workflow product for pharmacist-led distribution, with the app, reports, and consultation process doing much of the work.
Pricing in the public record is not fully consistent, which is worth treating carefully. RxGenomix's employer coalition page lists the employer-sponsored program at $299, reduced from $399, for qualifying members, while The Covington Reporter cited a $499 price point for the broader ExactMeds service in June 2024 [RxGenomix, December 2022] [The Covington Reporter, June 2024]. The difference may reflect channel-specific packaging rather than a contradiction, but the current public evidence does not establish a single durable list price.
No independent source found -- This section relies primarily on company product pages, with limited partial corroboration from one independent local news review [RxGenomix, May 2024] [RxGenomix] [RxGenomix, December 2022] [The Covington Reporter, June 2024].
The Market They Are Entering
PUBLIC
Pharmacogenomics sits at the intersection of rising prescription complexity and a healthcare system that is under more pressure to document avoidable medication harm, which is why the category merits attention even when company-specific traction remains thin in public records [ExactMeds by RxGenomix, retrieved 2024] [RxGenomix, May 2024].
The limiting fact in this section is straightforward: the source set does not include a named third-party market report with a defensible TAM, SAM, or SOM for ExactMeds specifically. On a public record, the demand signal has to be inferred from the company's stated target users, individuals, employers, benefit providers, pharmacists, and healthcare providers, rather than from audited market sizing [RxGenomix, December 2022] [ExactMeds, retrieved 2024]. That makes this less a precision sizing exercise and more a market-structure read on whether PGx-enabled medication management addresses a real budget line in benefits, pharmacy services, and telehealth.
What is visible is the shape of the wedge. ExactMeds is positioned not as a stand-alone lab test but as a service layer that combines at-home sample collection, laboratory PGx testing through accredited clinical labs, pharmacist interpretation, and a medication action plan [RxGenomix, May 2024] [RxGenomix]. That places it in an adjacent set of markets rather than one clean category: genetic testing, medication therapy management, employer-sponsored health benefits, and pharmacist-led telehealth all appear to be part of the purchasing logic [RxGenomix, December 2022] [The Covington Reporter, June 2024].
The immediate demand drivers in the public materials are also practical rather than speculative. The company frames the problem around medication mismatch and positions DNA-informed prescribing as a way to identify medications that may be more effective or safer for a given patient, with a pharmacist helping translate results into clinician-facing recommendations [RxGenomix, May 2024] [RxGenomix]. For employer and benefits channels, the public pitch is cost-contained access, including a coalition program listed at $299 for qualifying members, reduced from $399, and described as a covered benefit for eligible participants [RxGenomix, December 2022].
Regulatory and macro context matter here because PGx adoption depends on more than consumer interest. RxGenomix states that it operates as a PGx services company and works with accredited clinical testing laboratories, which suggests a market structure where clinical validity, test handling, and reimbursement pathways sit outside the company itself and can affect adoption speed [RxGenomix, May 2024]. The company's emphasis on pharmacist education, implementation support, and reimbursement guidance also points to a category constraint: workflow integration and payment mechanics may be as important as clinical interest in determining whether PGx becomes a recurring service rather than a one-off test [RxGenomix, December 2022].
| Public sizing or market-structure claim | Figure | Interpretation |
|---|---|---|
| U.S. adults using a daily prescription drug, as cited on ExactMeds homepage | 66% | Company-framed indication that the addressable medication-management population is broad, though not a third-party TAM figure [ExactMeds by RxGenomix, retrieved 2024] |
| Employer coalition program price | $299 | Public evidence of one employer-benefit pricing point, relevant to willingness-to-pay testing rather than market size [RxGenomix, December 2022] |
| Stated reduced price | $399 | Implies discounting in channel packaging, which may matter for benefits adoption economics [RxGenomix, December 2022] |
| Reported direct-to-consumer price in review coverage | $499 | Suggests a separate self-pay reference point outside the employer-sponsored channel [The Covington Reporter, June 2024] |
The table does not establish market size, but it does show where the public evidence is strongest: pricing architecture and broad medication exposure, not independently validated category volume. For investors, that shifts diligence toward reimbursement durability, employer uptake, and repeat engagement rather than headline TAM.
No independent source found -- This section relies mainly on company materials for market framing, adjacent-market positioning, and pricing, with one third-party review providing limited corroboration on consumer pricing [RxGenomix, December 2022] [RxGenomix, May 2024] [The Covington Reporter, June 2024].
The Competitive Field
The Competitive Field
MIXED ExactMeds is not competing for a single budget line so much as it is sitting between several established ones: pharmacogenomic testing, medication therapy management, telepharmacy, and employer health benefits, according to the company's own positioning across individual, provider, pharmacist, employer, and benefit channels [RxGenomix, December 2022] [RxGenomix, May 2024] [RxGenomix].
The practical consequence is that its alternatives are easier to name by category than by directly disclosed rival set. In the testing layer, the company does not present itself as a laboratory and says it works with accredited clinical testing laboratories, which suggests competition from lab-led pharmacogenomic offerings even if no lab competitors are named in the available materials [RxGenomix, May 2024]. In the care-delivery layer, it is asking buyers to choose a pharmacist-led interpretation and follow-up model over a one-time genetic report, with the company explicitly arguing that the pharmacist relationship is the differentiator rather than the test result alone [RxGenomix, December 2022] [RxGenomix].
That creates a narrower edge, but also a more legible one. Brad Tice's public profile is the clearest asset in the record: company materials identify him as founder and CEO, and independent public sources corroborate that he served as president of the American Pharmacists Association in 2019 to 2020 [RxGenomix, December 2022] [California Pharmacists Association, retrieved 2026] [Lead411, retrieved 2026]. For a product that depends on pharmacist adoption, reimbursement workflows, and clinical trust, that credibility likely matters more than it would in a direct-to-consumer genetics product. The difficulty is durability. The current edge appears to rest on professional standing, program design, and services integration, all of which can be copied faster than a proprietary dataset or a regulated testing moat if larger incumbents decide the segment is worth pursuing.
The company's clearest exposure is channel control. Public materials show outreach to employers, benefit providers, pharmacists, and individuals, plus one named employer partnership with Mechanics Bank in company materials and one anonymized 2022 insurance-related case study, but they do not establish a broad, independently verified customer roster or a dominant distribution partner [RxGenomix, retrieved 2026] [ExactMeds by RxGenomix, retrieved 2024]. That matters because adjacent substitutes already own pieces of the same workflow: clinicians can continue standard prescribing without PGx, pharmacies can offer conventional medication reviews, and employer-benefit consultants can slot in other specialty point solutions if they see stronger evidence or simpler implementation. The absence of named competitors in the disclosed record also limits how precisely one can map where ExactMeds is winning head-to-head versus where it is still defining the market for buyers.
The most plausible 18-month scenario is a bifurcation between credibility-led specialist programs and scaled distributors. ExactMeds is the likely winner if pharmacist-led medication management becomes the buying lens and employers or provider groups want a service layer wrapped around pharmacogenomic testing rather than a stand-alone lab output, because that is the company's stated design center today [RxGenomix, December 2022] [RxGenomix]. ExactMeds is the likely loser if the category consolidates around lab-branded or health-plan-integrated offerings with broader distribution and stronger published validation, because the public record here does not yet show funding scale, named institutional backers, or an independently verified deployment base that would offset those advantages.
Opportunity
Upside case
PUBLIC The prize here is not a better mail-order test, it is a chance to become the pharmacist-led operating layer for pharmacogenomics in employer benefits and medication management, if ExactMeds can turn a niche clinical service into a repeatable distribution model across plans, providers, and pharmacy channels [RxGenomix, December 2022] [RxGenomix, May 2024].
The headline opportunity is straightforward. ExactMeds is trying to package PGx testing, pharmacist interpretation, and follow-through with clinicians into one service, rather than selling a report and leaving the patient to act on it alone [RxGenomix, May 2024] [RxGenomix]. That matters because medication optimization is not only a testing problem, it is an implementation problem. The company already presents itself to multiple buyer groups, including individuals, healthcare providers, pharmacists, employers, and benefit providers, and it says it supports pharmacist education, implementation, and reimbursement workflows [RxGenomix, December 2022]. If that model works, the reachable upside is a scaled B2B2C platform that sits between lab output and medication decisions, especially in employer-sponsored care where ExactMeds is already marketed as a covered benefit rather than a one-off consumer purchase [RxGenomix, December 2022] [ExactMeds by RxGenomix, retrieved 2024].
The public evidence does not yet prove scale, but it does show the shape of a distribution strategy that could compound. ExactMeds has a direct-to-consumer price point cited at $499 in one independent local report, while the employer-sponsored version is listed at $299, reduced from $399, and described by the company as fully covered for qualifying members [The Covington Reporter, June 2024] [RxGenomix, December 2022]. That spread suggests management understands the category is more likely to expand through sponsored access and channel partners than through pure cash-pay consumer demand. The company also cites a 2022 case study with "one of the world’s largest insurance companies," although the insurer is unnamed, which is not enough to confirm commercial traction but does indicate an effort to sell into institutional healthcare buyers rather than remaining a retail testing product [ExactMeds by RxGenomix, retrieved 2024].
| Scenario | What happens | Catalyst | Why its plausible |
|---|---|---|---|
| Employer-benefit wedge | ExactMeds becomes a recurring specialty benefit for self-insured employers and coalition-style purchasing groups, with PGx testing tied to pharmacist consults for members using chronic prescriptions | A named employer or benefits intermediary expands a pilot into a broader covered program [RxGenomix, December 2022] | The company already markets ExactMeds as an employer and benefit-provider program, lists sponsored pricing, and cites at least one employer partnership example through Mechanics Bank and the Know Your Rx Coalition materials [RxGenomix, December 2022] [RxGenomix, retrieved 2026] |
| Pharmacist-channel platform | ExactMeds becomes the default PGx service layer independent pharmacists can add to practice, with training, implementation support, and reimbursement guidance bundled in | Wider adoption of pharmacist-billed PGx consultations through existing pharmacy workflows [RxGenomix, December 2022] [RxGenomix] | This is already how the company describes its wedge. It is not positioning as a lab, but as a services company working with accredited clinical testing laboratories and enabling pharmacists to deliver the consultative layer [RxGenomix, May 2024] [RxGenomix, December 2022] |
| Insurer-enabled medication management | ExactMeds wins a health-plan or PBM-style relationship where PGx becomes part of medication safety and efficacy programs for targeted populations | A named payer deployment or published outcomes study that links PGx-guided changes to lower medication waste or adverse drug events [ExactMeds by RxGenomix, retrieved 2024] | The 2022 insurer case study is incomplete evidence, but it shows the company is already framing the product as a population-health tool, not only an individual wellness purchase [ExactMeds by RxGenomix, retrieved 2024] [ExactMeds, retrieved 2024] |
The compounding mechanism would come from services density rather than pure software scale. Each employer, pharmacist, or benefits partner could add members or patients into the same workflow, while every completed consult improves the company’s practical playbook for medication review, clinician coordination, and benefit design [RxGenomix, December 2022] [RxGenomix]. Because RxGenomix says it is lab-agnostic and works with accredited clinical testing laboratories, it may have a cleaner path to becoming the interpretation and care-navigation layer rather than bearing the full burden of lab operations itself [RxGenomix, May 2024]. If the pharmacist relationship is what drives trust and action, then the flywheel is: sponsored distribution lowers patient acquisition cost, pharmacist consults improve usability of PGx results, better usability supports renewals or program expansion, and expansion attracts more pharmacists and institutional buyers. The public record only shows the early ingredients of that loop, not proof that it is already turning at scale [RxGenomix, December 2022] [The Covington Reporter, June 2024].
The size of the win is best framed qualitatively because this source set does not contain a cited market-size study or a clean public comparable. In the strongest public scenario, ExactMeds could become a meaningful niche platform in medication optimization for employers and pharmacy partners, with value driven by channel control and clinical workflow ownership rather than by testing alone (scenario, not a forecast). A more ambitious version of that same scenario would resemble a strategic asset for a pharmacy services company, benefits platform, digital health navigator, or payer-facing care-management vendor that wants a pharmacist-led PGx capability in-house [RxGenomix, December 2022] [RxGenomix, May 2024]. The missing piece is independent proof of customer density, outcomes, and repeatability. If those appear, the upside case becomes easier to underwrite on distribution rather than on the underlying science, which is a materially better place for a young company to sit.
No independent source found -- This section relies primarily on company materials, with limited independent corroboration from The Covington Reporter and directory-style third-party references.
Sources
Publicly reported
[ExactMeds by RxGenomix, retrieved 2024] ExactMeds by RxGenomix | https://exactmeds.com/
[RxGenomix, May 2024] Individuals/Patients | https://rxgenomix.com/audience/patient-individual/
[RxGenomix, December 2022] About | https://rxgenomix.com/about/
[LinkedIn, retrieved 2024] RxGenomix | LinkedIn | https://www.linkedin.com/company/rxgenomix
[RxGenomix] ExactMeds App | https://rxgenomix.com/exactmeds-app/
[California Pharmacists Association, retrieved 2026] Brad Tice - California Pharmacists Association | https://cpha.com/
[Lead411, retrieved 2026] Lead411 | https://www.lead411.com/
[LinkedIn, retrieved 2026] Md. Mahmudul Hasan - Oklahoma State University | LinkedIn | https://www.linkedin.com/
[The Covington Reporter, June 2024] ExactMeds by RxGenomix Review - Everything You Need To Know | https://www.covingtonreporter.com/2024/06/06/exactmeds-by-rxgenomix-review-everything-you-need-to-know/
[ExactMeds, retrieved 2024] Get Started With ExactMeds | https://exactmeds.com/product/exactmeds/
[RxGenomix, retrieved 2026] RxGenomix | https://rxgenomix.com/
[The Covington Reporter, June 20] ExactMeds by RxGenomix Review - Everything You Need To Know | https://www.covingtonreporter.com/2024/06/06/exactmeds-by-rxgenomix-review-everything-you-need-to-know/
Articles about ExactMeds by RxGenomix
- RxGenomix's ExactMeds Puts a Pharmacist in the Loop of Genetic Testing — The unfunded startup, led by a former APhA president, is betting that counseling is the missing link for pharmacogenomics to improve medication safety.